Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes

被引:20
作者
Rapoport, AP
Simons-Evelyn, M
Chen, T
Sidell, R
Luhowskyj, S
Rosell, K
Obrig, T
Hicks, D
Hinkle, PM
Nahm, M
Insel, RA
Abboud, CN
机构
[1] Univ Maryland, Med Ctr, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[2] Univ Rochester, Sch Med & Dent, Dept Med, Hematol Oncol Unit, Rochester, NY 14642 USA
[3] Univ Rochester, Sch Med & Dent, Dept Microbiol, Rochester, NY 14642 USA
[4] Univ Rochester, Sch Med & Dent, Dept Pathol, Rochester, NY 14642 USA
[5] Univ Rochester, Sch Med & Dent, Dept Biol, Rochester, NY 14642 USA
[6] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA
关键词
Burkitt's lymphoma; flavopiridol; flavones; caspase-3; apoptosis; p53; Shiga toxin; cell lines;
D O I
10.1006/bcmd.2001.0428
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Burkitt's lymphoma cell lines have been important in vitro models for studying the pathogenesis of Burkitt's lymphoma (BL) and for exploring new treatment strategies. A new EBV(-) Burkitt's lymphoma cell line (GA-10) was established from a patient with a clinically aggressive, chemorefractory BL and characterized. Although functional p-glycoprotein could not be demonstrated by dye-efflux assays, both p53 genes were mutated in the GA-10 cells, perhaps contributing to the resistant phenotype of the original neoplasm. Two properties of BL cells which may be useful targets for novel cytotoxic therapeutics are their surface expression of CD77, the receptor for Shiga toxin (Stx), and their high rate of proliferation. Expression of CD77 on the GA-10 cells was heterogeneous in that certain subclones expressed high levels of CD77 and correspondingly exhibited strong growth inhibition by Stx while others showed low levels of CD77 expression and weak Stx-induced growth inhibition. Flavopiridol, a potent inhibitor of cell cycle progression through G1 and G2, induced cytotoxicity of the GA-10 cells with an LC50 of approximately 40 nM vs 70 nM for HL-60 cells (P < 0.05). The concentrations of flavopiridol at which only 10% of the cells were viable (LC10) were approximately 280 nM for the GA-10 cells and 520 nM for the HL-60 cells (P < 0.05). Dose-related induction of apoptosis in response to flavopiridol was demonstrated in the GA-10 cells by morphology, TUNEL assay, and activation of caspase-3. Flavopiridol was also cytotoxic to seven other BL cell lines tested. These data suggest that flavopiridol may have therapeutic value in the treatment of Burkitt's lymphoma. (C) 2001 Academic Press.
引用
收藏
页码:610 / 624
页数:15
相关论文
共 67 条
[1]
DNA-DAMAGE IN HUMAN B-CELLS CAN INDUCE APOPTOSIS, PROCEEDING FROM G(1)/S WHEN P53 IS TRANSACTIVATION COMPETENT AND G(2)/M WHEN IT IS TRANSACTIVATION DEFECTIVE [J].
ALLDAY, MJ ;
INMAN, GJ ;
CRAWFORD, DH ;
FARRELL, PJ .
EMBO JOURNAL, 1995, 14 (20) :4994-5005
[2]
Arguello F, 1998, BLOOD, V91, P2482
[3]
BAE IS, 1995, CANCER RES, V55, P2387
[4]
COMBINED MODALITY THERAPY FOR ADULTS WITH SMALL NONCLEAVED CELL LYMPHOMA (BURKITTS AND NON-BURKITTS TYPES) [J].
BERNSTEIN, JI ;
COLEMAN, CN ;
STRICKLER, JG ;
DORFMAN, RF ;
ROSENBERG, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) :847-858
[5]
HEMIZYGOSITY OR HOMOZYGOSITY - A REQUIREMENT FOR SOME BUT NOT OTHER P53 MUTANT PROTEINS TO ACCUMULATE AND EXERT A PATHOGENETIC EFFECT [J].
BHATIA, K ;
GOLDSCHMIDTS, W ;
GUTIERREZ, M ;
GAIDANO, G ;
DALLAFAVERA, R ;
MAGRATH, I .
FASEB JOURNAL, 1993, 7 (10) :951-956
[6]
Bible KC, 1996, CANCER RES, V56, P4856
[7]
Bible KC, 1997, CANCER RES, V57, P3375
[8]
ASSOCIATION BETWEEN CIGARETTE-SMOKING AND MUTATION OF THE P53 GENE IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BRENNAN, JA ;
BOYLE, JO ;
KOCH, WM ;
GOODMAN, SN ;
HRUBAN, RH ;
EBY, YJ ;
COUCH, MJ ;
FORASTIERE, AA ;
SIDRANSKY, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (11) :712-717
[9]
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 [J].
Byrd, JC ;
Shinn, C ;
Waselenko, JK ;
Fuchs, EJ ;
Lehman, TA ;
Nguyen, PL ;
Flinn, IW ;
Diehl, LF ;
Sausville, E ;
Grever, MR .
BLOOD, 1998, 92 (10) :3804-3816
[10]
Carlson BA, 1996, CANCER RES, V56, P2973